1
|
Luo X. Nanobiotechnology-based strategies in alleviation of chemotherapy-mediated cardiotoxicity. ENVIRONMENTAL RESEARCH 2023; 238:116989. [PMID: 37633635 DOI: 10.1016/j.envres.2023.116989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 08/19/2023] [Accepted: 08/23/2023] [Indexed: 08/28/2023]
Abstract
The cardiovascular diseases have been among the most common malignancies and the first leading cause of death, even higher than cancer. The cardiovascular diseases can be developed as a result of cardiac dysfunction and damages to heart tissue. Exposure to toxic agents and chemicals that induce cardiac dysfunction has been of interest in recent years. The chemotherapy drugs are commonly used for cancer therapy and in these patients, cardiovascular diseases have been widely observed that is due to negative impact of chemotherapy drugs on the heart. These drugs increase oxidative damage and inflammation, and mediate apoptosis and cardiac dysfunction. Hence, nanotechnological approaches have been emerged as new strategies in attenuation of chemotherapy-mediated cardiotoxicity. The first advantage of nanoparticles can be explored in targeted and selective delivery of drugs to reduce their accumulation in heart tissue. Nanostructures can deliver bioactive and therapeutic compounds in reducing cardiotoxicity and alleviation toxic impacts of chemotherapy drugs. The functionalization of nanostructures increases their selectivity against tumor cells and reduces accumulation of drugs in heart tissue. The bioplatforms such as chitosan and alginate nanostructures can also deliver chemotherapy drugs and reduce their cardiotoxicity. The function of nanostructures is versatile in reduction of cardiotoxicity by chemotherapy drugs and new kind of platforms is hydrogels that can mediate sustained release of drug to reduce its toxic impacts on heart tissue. The various kinds of nanoplatforms have been developed for alleviation of cardiotoxicity and their future clinical application depends on their biocompatibility. High concentration level of chitosan nanoparticles can stimulate cardiotoxicity. Therefore, if nanotechnology is going to be deployed for drug delivery and reducing cardiotoxicity, the first pre-requirement is to lack toxicity on normal cells and have high biocompatibility.
Collapse
Affiliation(s)
- Xuanming Luo
- Department of General Surgery, Zhongshan Hospital, Fudan University, China; Department of General Surgery, Shanghai Xuhui Central Hospital, Fudan University, China; Biliary Tract Disease Center of Zhongshan Hospital, Fudan University, China; Cancer Center, Zhongshan Hospital, Fudan University, China; Biliary Tract Disease Institute, Fudan University, China; Shanghai Engineering Research Center of Biliary Tract Minimal Invasive Surgery and Materials, China.
| |
Collapse
|
2
|
Nolan MT, Creati L, Koczwara B, Kritharides L, Lynam J, Lyon AR, Negishi K, Ngo DTM, Thomas L, Vardy J, Sverdlov AL. First European Society of Cardiology Cardio-Oncology Guidelines: A Big Leap Forward for an Emerging Specialty. Heart Lung Circ 2022; 31:1563-1567. [PMID: 36549840 DOI: 10.1016/j.hlc.2022.11.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Mark T Nolan
- Department of Medicine, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia; Cardiovascular Imaging Department, Baker Heart and Diabetes Institute, Melbourne, Vic, Australia. https://twitter.com/drmarknolan
| | - Louise Creati
- Department of Medicine, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
| | - Bogda Koczwara
- Department of Oncology, Flinders Medical Centre, Adelaide, SA, Australia. https://twitter.com/bogda_koczwara
| | - Leonard Kritharides
- Department of Cardiology, Concord Repatriation General Hospital, Sydney, NSW, Australia
| | - James Lynam
- Department of Medical Oncology, Calvary Mater Hospital, Newcastle, NSW, Australia; College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW, Australia; Newcastle Centre of Excellence in Cardio-Oncology, Hunter Medical Research Institute, Newcastle, NSW Australia
| | - Alexander R Lyon
- Cardio-Oncology Service, Royal Brompton Hospital; London, National Heart and Lung Institute, Imperial College London, London, UK
| | - Kazuaki Negishi
- Sydney Medical School Nepean, Faculty of Medicine and Health, Charles Perkins Centre Nepean, The University of Sydney, Sydney, NSW, Australia. https://twitter.com/kaznegishi
| | - Doan T M Ngo
- College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW, Australia; Newcastle Centre of Excellence in Cardio-Oncology, Hunter Medical Research Institute, Newcastle, NSW Australia. https://twitter.com/DoanNgo4
| | - Liza Thomas
- Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia; Westmead Clinical School, University of Sydney, South Western Clinical School, University of New South Wales, Sydney, NSW, Australia
| | - Janette Vardy
- Concord Cancer Centre, Concord Repatriation General Hospital, Sydney, NSW, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. https://twitter.com/janette_vardy
| | - Aaron L Sverdlov
- College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW, Australia; Newcastle Centre of Excellence in Cardio-Oncology, Hunter Medical Research Institute, Newcastle, NSW Australia; Cardiovascular Department, John Hunter Hospital, Newcastle, NSW, Australia.
| |
Collapse
|
3
|
Ferreira VV, Cardoso I, Ângelo I, Feliciano J, Mano TB, Rosa SA, Almeida-Morais L, Branco LM, Thomas B, Ferreira RC. Cardio-Oncology in Portugal. JACC CardioOncol 2022; 4:417-420. [PMID: 36213352 PMCID: PMC9537068 DOI: 10.1016/j.jaccao.2022.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Accepted: 06/01/2022] [Indexed: 11/09/2022] Open
|
4
|
2021 top 10 articles in the Arquivos Brasileiros de Cardiologia and the Revista Portuguesa de Cardiologia. Rev Port Cardiol 2022; 41:611-620. [DOI: 10.1016/j.repc.2022.06.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Accepted: 05/24/2022] [Indexed: 11/18/2022] Open
|
5
|
Fontes-Carvalho R, Oliveira GMMD, Gonçalves-Teixeira P, Rochitte CE, Cardim N. 2021 Top 10 Articles in the Arquivos Brasileiros de Cardiologia and the Revista Portuguesa de Cardiologia. Arq Bras Cardiol 2022; 119:113-123. [PMID: 35830110 PMCID: PMC9352128 DOI: 10.36660/abc.20220312] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Accepted: 05/24/2022] [Indexed: 12/04/2022] Open
Affiliation(s)
- Ricardo Fontes-Carvalho
- Departamento de Cardiologia - Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia/Espinho - Portugal.,Cardiovascular Research Center (UniC), Faculty of Medicine, University of Porto, Porto, Portugal
| | - Gláucia Maria Moraes de Oliveira
- Faculdade de Medicina - Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ - Brasil.,Instituto do Coração Edson Saad - Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ - Brasil
| | - Pedro Gonçalves-Teixeira
- Departamento de Cardiologia - Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia/Espinho - Portugal.,Cardiovascular Research Center (UniC), Faculty of Medicine, University of Porto, Porto, Portugal
| | - Carlos Eduardo Rochitte
- Instituto do Coração (InCor) - Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP - Brasil.,Hospital do Coração (HCOR), São Paulo, SP - Brasil
| | | |
Collapse
|